SDSU, Boehringer Ingelheim team up against enterotoxic E. coli
South Dakota State University is partnering with animal health leader Boehringer Ingelheim Vetmedica, Inc. to develop a new technology to protect pigs against a deadly form of E. coli.
Page 18 of articles about vaccine
Eradication of FMD in the Philippines (II)
In 1996, the NFMDTF drafted a national plan to address the 1995 FMD epidemic wherein 98,000 animals were reported to have been affected.
Merck Animal Health breaks ground for $18 million vaccine plant expansion
Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, announced today that it has embarked on the expansion of a vaccine manufacturing unit at its Biosciences Center Boxmeer campus in the Netherlands.
Eradication of FMD in the Philippines (I)
The FMD Eradication Project in the Philippines has formally ended but activities have been sustained even after obtaining FMD-freedom in Luzon having no clinical cases for 5 years with the last outbreak recorded in December 28, 2005.
Bioniche chief veterinary scientific officer discusses vaccine against E. coli O157 at International meat industry conference
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Chief Veterinary Scientific Officer, Dr. Dragan Rogan, was an invited speaker at the 56th International Meat Industry Conference being held in Tara, Serbia.
Vietnam boosts animal vaccine reserve
Vietnam’s prime minister has allocated an additional VND 70.6 billion (USD3.36 million) for the Ministry of Agriculture and Rural Development to buy animal-disease vaccine and disinfection chemicals for national reserve in 2011.
Improved vaccine against progressive atrophic rhinitis in swine launched by Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health announces today that it is introducing PORCILIS® AR-T DF, an inactivated vaccine against progressive atrophic rhinitis in piglets with a new adjuvant associated with fewer injection site reactions.
Animal Health and Food Safety vaccine manufacturing centre officially opens in Belleville, Ontario, Canada
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada.
Field study confirms protection of piglets against porcine circovirus associated disease by vaccination with Porcilis® PCV
Intervet/Schering-Plough Animal Health announces today that a field trial with the single-dose subunit vaccine PORCILIS® PCV has confirmed that vaccination induces humoral and cellular immunity and protects piglets against the consequences of porcine circovirus-associated disease (PCVD).
Virbac to distribute Prevtec microbia's innovative Coliprotec® vaccine in Brazil
Virbac, the 8th largest veterinarian pharmaceutical group worldwide, has concluded an exclusive Distribution and Trademark Licence Agreement with Prevtec microbia, a Canadian veterinarian laboratory, for the distribution of the Coliprotec® vaccine in Brazil.
North Korea - FAO says urgent vaccine and equipment needed to contain Foot-and-Mouth Disease
Around a million dollars of equipment and vaccines are urgently required to help stem outbreaks of deadly Foot-and-Mouth disease (FMD) in North Korea, followed by a more prolonged and concerted effort to modernize veterinary services in the country.
China plans compulsory animal vaccination
The Ministry of Agriculture and Ministry of Finance jointly filed a new regulation on animal vaccination for prevention of epidemic diseases in 2011.
Intervet/Schering-Plough Animal Health completes delivery of 12 million doses of foot-and-mouth vaccine to the government of South Korea
Intervet/Schering-Plough Animal Health announces today that it has shipped 12 million doses of foot-and-mouth disease (FMD) vaccine to South Korea to assist in the country’s efforts to halt the ongoing FMD outbreak.
Maternally derived antibodies at the time of porcine circovirus type 2 vaccination: does it matter?
One issue is to overcome maternal immunity, which is true for all PCV2 vaccines in the market, and another is whether the most from these vaccines is achieved independently of the PCV2 antibody titre at vaccination
A piglet claim for CIRCOVAC® in Europe
On November 29th 2010, CIRCOVAC was granted a European marketing authorization for use in piglets. CIRCOVAC is now the first PCVD vaccine available worldwide for the vaccination of both sows and piglets; it is registered in Europe, Brazil, Mexico and Thailand.
Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae
rCap expressed in T. ni larvae could be a cost-effective PCV2 vaccine candidate to be tested under field conditions.